Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch

Nuvation Bio Inc. (NYSE:NUVB) is one of the best low cost stocks to buy under $5. On March 2, Nuvation Bio (NUVB) reported a pivotal 2025 marked by the FDA approval and rapid commercial launch of Ibtrozi (Taletrectinib) for ROS1-positive non-small cell lung cancer. With 432 new patient starts by year-end, the drug’s uptake outpaced prior class competitors by sixfold. Financially, the company reported $41.9 million in Q4 revenue, supported by a strong cash position of $529.2 million following international partnerships with Eisai and Nippon Kayaku.

While early revenue was impacted by a high volume of late-line patients with shorter treatment durations, management expects revenue stability to improve as first-line patient penetration increases through 2026. The company is emphasizing Ibtrozi’s differentiated clinical profile, specifically its 50-month median duration of response in TKI-naive patients and its favorable safety profile. The CEO highlighted the drug’s unique measured inhibition of TRKB, which supports intracranial disease control while avoiding the severe neurological toxicities seen in other therapies.

To expand the drug’s reach, Nuvation Bio has initiated the TRUST-4 Phase 3 study in the adjuvant setting, targeting early-stage patients who require high tolerability for long-term adherence. Beyond Ibtrozi, Nuvation Bio Inc. (NYSE:NUVB) is advancing its second lead program, safusidenib, for IDH1-mutant glioma. The company recently launched the Phase 3 SIGMA trial for high-grade patients, who currently have no approved targeted options, with a projected readout in 2029. Additionally, a smaller Phase 2 cohort for grade 3 oligodendroglioma is underway with results expected by 2027, potentially offering an accelerated approval pathway.

Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company that develops therapeutic candidates for oncology. Its lead product candidate is taletrectinib, which is an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.

While we acknowledge the potential of NUVB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.